Dicot Pharma AbOMXSTO: DICOT

Dicot Pharma Gets FDA Clearance To Start First Part Of Phase 2B Study With Lib-01 In U.S.

· Issued by Dicot Pharma Ab

Dicot Pharma AB OMXSTO:DICOT:

  • RECEIVES FDA CLEARANCE TO INITIATE THE FIRST PART OF THE PHASE 2B STUDY WITH LIB-01 IN THE U.S.

  • APPLICATION TO COMMENCE STUDY IN EUROPE WILL BE SUBMITTED TO RELEVANT REGULATORY AUTHORITIES IN Q3

  • STUDY IS EXPECTED TO START IN SECOND HALF OF 2026, IN LINE WITH PREVIOUSLY COMMUNICATED TIMELINE

Earlier from Dicot Pharma Ab

All Dicot Pharma Ab news releases